Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I like your thinking, I've got that feeling too. Go $grps
Saw this today on sister JV company, ultimately good for GRPS if it works out.
stervc Member Level
Tuesday, 05/12/20 02:48:14 PM
Re: 3CTraderIsBack post# 17742 0
Post #
17746
of 17751
With this HALB "Map and ZapTM" News...
This is good news for HALB in my opinion:
Quote:
https://www.otcmarkets.com/stock/HALB/news/story?e&id=1600688
Premier Biomedical, Technology Health, and Datatecnics Agree to Collaborate on Extracorporeal "Map and Zap(TM)" Coronavirus Treatment
JACKSON CENTER, PA / ACCESSWIRE / May 12, 2020 / Premier Biomedical, Inc. (OTC PINK:BIEI) and Technology Health, Inc. (OTC PINK:HALB) announced today an agreement to pursue a novel coronavirus extracorporeal treatment which combines Premier Biomedical's antigen mapping technique with Datatecnics' laser ablation technology in a focused "Map and ZapTM" treatment protocol disclosed in a provisional patent application that is intended to eliminate COVID-19 antigens and potential mutations. Research is expected to start this quarter to develop complexing agents to bind with coronavirus antigens which can be illuminated and eliminated using a computer-controlled targeting and laser system. The proposed hospital/clinic process would illuminate the compounded molecular target disease antigens for destruction by a nano-focus laser, and the purified blood would then be returned to the patient.
Dr. Mitchell Felder, inventor of the patented extracorporeal treatment process (U.S. Patent 9,216,386 and U.S. Patent 8,758,287), indicated, "Our first step in bringing this "Map & Zap™" process to fruition is to develop the biomarkers which can bind to the target coronavirus antigen molecules in the blood. We are very confident, that together with our university partners, we can identify and produce the requisite biomarkers in a relatively short period of time. This process is embodied in the provisional patents entitled: "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients" and "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus."
Dr. Felder continued with the following observations speaking to the innovation and likely longevity and safety factors attending this approach: "This technological breakthrough is unique in that it offers two critically distinct advantages over any conventional therapy:
Rapid adjustment to conform to any future virus. As flu and cold strains change over time, however imperceptibly, a new treatment is necessitated. That's why last year's flu vaccine is often ineffective against this year's flu strain. On the other hand, our technology can be a game-changer as we endeavor to simply and rapidly adjust to the targeted antigens and to conform to any mutations.
In our methodology, no vaccines or internal medicines are required and, therefore, side-effects are virtually eliminated. Our extracorporeal "treatment" is performed outside the body, much like a dialysis machine. The cleansed blood is then returned to the patient after the dangerous elements are removed. No pills or chemicals are administered to the patient. For this reason, we anticipate an accelerated FDA review process."
Mohammed Zulfiquar, a world renowned inventor (holder of over 100 patents) and Founder and CEO of Datatecnics, a privately held UK-based company, stated, "We are excited to apply our unique nano laser capabilities and magnification technology to the extracorporeal treatment process to help defeat the coronavirus pandemic."
William A. Hartman, President & CEO of Premier Biomedical, Inc., added, "We believe we have a unique, viable approach in that we are combining two proven technologies - Premier Biomedical's ability, along with our research university partner, to develop complexing agents to target and bind to specific disease-causing antigens, and Datatecnics' extensive capabilities in nano science and laser systems. The urgency in overcoming the COVID-19 pandemic is driving the entire multi-company team's efforts to produce results, and we are doing everything possible to deliver in the shortest period of time."
Technology Health, Inc., formerly Halberd, Inc., facilitated the cooperative relationship between Premier Biomedical and Datatecnics and has acquired the patented technology for extracorporeal treatment of COVID-19.
For more information please contact:
William A. Hartman
President and CEO
Premier Biomedical Inc.
(724) 633-7033
w.hartman@premierbiomedical.com
www.premierbiomedical.com
For more information regarding Technology Health, Inc. please contact:
James Christopher LeDoux, CEO
Technology Health, Inc., formerly Halberd Corporation
support@technologyhealthinc.com
www.Technologyhealthinc.com
Twitter: @techhealthinc
About Technology Health, Inc.
Technology Health, Inc. (HALB), formerly Halberd, Inc., is a publicly traded company on the OTC Market and intends to be a fully reporting entity. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology (U.S. Patent 9,216,386 and U.S. Patent 8,758,287) and the exclusive rights to the provisional patents "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients" and "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus".
About Datatecnics Corp., Ltd.
Datatecnics is a privately held UK-based company, established in 2011. The founder and holder of over one hundred patents, Mohammed Zulfiquair, invented CIPPS (Critical Infrastructure Pipeline Protection System) technology that converts dumb metal surfaces into intelligent self-reporting infrastructure which can communicate big data via M2M (Machine to Machine) or to central control systems. The company is a leader in printed sensors and nano science.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTC-PINK:BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company's R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTC marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI." For more information please visit our websites: http://www.premierbiomedical.com and http://www.painreliefmeds.com
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: Premier Biomedical, Inc.
View source version on accesswire.com:
https://www.accesswire.com/589461/Premier-Biomedical-Technology-Health-and-Datatecnics-Agree-to-Collaborate-on-Extracorporeal-Map-and-ZapTM-Coronavirus-Treatment
v/r
Sterling
I think you're spot on, the longs here have most of the float tucked away.
Thank you for your time spent doing some great detective work. Between you and Stervc I've learned much more about the company.
That's all it'll take
...
Seemed sorta cryptic to me. I wonder why it was sent? Is there more to come on Thursday? We all know we can't make specific health claims for natural supplements or we provoke the wrath of the FDA.
Thank you for going the extra mile and digging into this for us. We appreciate it.
Let's go GRPS with our graphene farming. Here's another exciting use for it.
https://phys.org/news/2020-03-crumpled-graphene-ultra-sensitive-cancer-dna.html
Great post, thank you. To pennies and more..
Wishing you well gringhez, stay healthy.
This is true, good luck to all.
Go $GRPS
Sounds awesome to me, just waiting and holding for silver and beyond.
Graphene is going to be king here one day, wheels are turning...
JMHO....go $GRPS
Much more to come. Grants are still in play, a defense contractor testing pain patches, possible acquisitions, a smart and confident management team...
JMHO. Go $GRPS
IMO much more to come. Grants still in play, possible acquisitions and a confident mgmt. team...02's were tempting but the future holds more, I believe.
IMO. Go $GRPS
Right on! Waited along time for this day, ain't it great?
Good information sir, thank you.
Gold is coming, Go GRPS!
Great news today, thank you Dr. Goulding! I'm glad I was able to add more this morning.
Hoping this research continues and new products are developed and get to market. Let's hope big pharma doesn't screw things up.
Just read this report, I hope it works out for these researchers.
Researchers at McMaster University in Canada have discovered that cannabigerol (CBG) is capable of defeating MRSA, an infection infamously resistant to many traditional antibiotics.
Researchers from McMaster University in Canada say that cannabigerol (CBG), a cannabinoid found in hemp and cannabis plants, has antibacterial properties and has been shown to defeat a family of bacteria known as methicillin-resistant Staphylococcus aureus (MRSA).
I just read this report, interesting information.
The findings, published in the journal American Chemical Society Infectious Diseases, suggest that CBG could become a breakthrough treatment for MRSA, an infamously drug-resistant infection.
In the study, researchers managed to cure MRSA infections among mice using CBG, which “proved to be marvelous at tackling pathogenic bacteria,” said Brown. “The findings suggest real therapeutic potential for cannabinoids as antibiotics.”
The research team noted that the toxicity of CBG on host cells pose a hiccup in their findings, but that its antibiotic properties are more than enough to warrant further research.
“It opens a therapeutic window, but a narrow one, to develop this into a drug,” said Brown. “The next steps are to try to make the compound better in that it is more specific to the bacteria and has a lower chance of toxicity.”
McMaster University researchers have been investigating the antibiotic properties of cannabinoids for the two years since Canada legalized cannabis nationwide.
“In this study, we investigated 18 commercially available cannabinoids and they all showed antibiotic activity, some much more than others. The one we focused on was a non-psychoactive cannabinoid called CBG, as it had the most promising activity. We synthesized that cannabinoid in mass quantity which gave us sufficient compound to go deep into the research.” — Eric Brown, lead study author and professor of biochemistry and biomedical sciences at McMaster
Thanks for the cheapies, but I need a few more.
Great post and well considered.
Thanks for sharing sroks5.
Well said, thank you.
Hope that hemp-carbon farming grant gets approved soon. Looks like another use for graphene has been developed.
phys.org/news/2019-12-tech-jewel-graphene-diamond
Thank you for sharing that info. I may to add to add to my stash now.
Go $GRPS
Go $GRPS. Expecting a great day.
GO $GRPS. Future 2020 penny stock of the year IMHO.
I bet we get news within the next month.
Should be alot more eyes on this tomorrow.
I'd sure hope so, that's one of the finest cancer hospitals in the nation.
Thanks for posting this news. I just got the message too.
When I asked a few weeks ago, his answer was Very soon.
You're right, we're starting to see the pieces.
Gold River Productions
We are a collective organization of physicians, scientists, logistics experts, and networkers with a unique ability to assemble projects with huge potential income.
With sister company, RSHN we have a sizeable investor base of over 40,000. These are individuals with skin already in the game. Our links to finance, CBD growth and cultivation, nutraceuticals, defense, lobbyists, transportation and more has afforded us unique opportunities in a wide array of fields that can be exponentially lucrative.
Great info, thanks.
Well, on second look I guess it's not fully finished yet. All the links aren't re-directing. The website builder must be waiting for final approval to add the missing pieces. I'd say this bodes well for us.
I see that www.grpsinc.com is live and working now. Let's hope this week is full of news.
New tweet just out from XYZHemp.
great post, just what we need.